Various Approaches Employed to Enhance the Bioavailability of Antagonists Interfering with the HMGB1/RAGE Axis
Open Access
- 2 August 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 5 (3) , 35
Abstract
High-mobility group box 1 (HMGB1) is a nuclear protein that can interact with a transmembrane cell surface receptor for advanced glycation end products (RAGEs) and mediates the inflammatory pathways that lead to various pathological conditions like cancer, diabetes, cardiovascular diseases, and neurodegenerative disorders. Blocking the HMGB1/RAGE axis using various small synthetic or natural molecules has been proven to be an effective therapeutic approach to treating these inflammatory conditions. However, the low water solubility of these pharmacoactive molecules limits their clinical use. Pharmaceutically active molecules with low solubility and bioavailability in vivo convey a higher risk of failure for drug development and drug innovation. The pharmacokinetic and pharmacodynamics parameters of these compounds are majorly affected by their solubility. Enhancement of the bioavailability and solubility of drugs is a significant challenge in the area of pharmaceutical formulations. This review mainly describes various technologies utilized to improve the bioavailability of synthetic or natural molecules which have been particularly used in various inflammatory conditions acting specifically through the HMGB1/RAGE pathway.Keywords
This publication has 107 references indexed in Scilit:
- Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitorsDrug Development Research, 2022
- Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidenceBiomedicine & Pharmacotherapy, 2021
- Nano strategies for berberine delivery, a natural alkaloid of BerberisBiomedicine & Pharmacotherapy, 2018
- Composite chitosan hydrogels for extended release of hydrophobic drugsCarbohydrate Polymers, 2016
- Synthesis, antimalarial activity and cytotoxic potential of new monocarbonyl analogues of curcuminBioorganic & Medicinal Chemistry Letters, 2013
- Absorption, metabolism, and excretion of green tea flavan‐3‐ols in humans with an ileostomyMolecular Nutrition & Food Research, 2010
- Absorption, metabolism and excretion of Choladi green tea flavan‐3‐ols by humansMolecular Nutrition & Food Research, 2009
- Antioxidant and radical scavenging properties of curcuminChemico-Biological Interactions, 2008
- Efficient Co-crystal Screening Using Solution-Mediated Phase TransformationJournal of Pharmaceutical Sciences, 2007
- A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (−)-epigallocatechin gallate [(−)-EGCG]Bioorganic & Medicinal Chemistry, 2004